Frontlight ResearchEarly access
Lung cancer trials in South Korea
170 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleGenomic Analysis to Identify a Predictive Biomarker for Immunotherapy
- Where
- Seoul
- Age
- 18 years and over
- People
- 2,000
- Run by
- Samsung Medical Center
See details and how to joinNCT03578185 - Phase 3Taking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - Phase 1Taking peopleAMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- Amgen
See details and how to joinNCT07094113 - Phase 2Taking peopleDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Seoul
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - Phase 2Taking peopleNelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
- Where
- Gyeonggi-do, Seoul
- Age
- 19 years and over
- People
- 62
- Run by
- STCube, Inc.
See details and how to joinNCT07306624 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Cheongju-si, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - Phase 1Taking peopleA Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- PAQ Therapeutics, Inc.
See details and how to joinNCT07300150 - Phase 2Taking peopleAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- Incheon, Seoul
- Age
- 18 years to 70 years
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Goyang-si, Seongnam, Seoul
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - Phase 1/2Taking peopleClinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 80
- Run by
- Yuhan Corporation
See details and how to joinNCT06975410 - Phase 1Taking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00 - No phaseTaking peopleA Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
- Where
- Busan, Daegu, Daejeon, Incheon, Jeollanam, Seoul, Suwon
- Age
- 18 years to 100 years
- People
- 44
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05703516 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Cheongju-si, Hwasun-eup, Hwasun-gun, Seoul
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 1/2Taking peopleA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- Where
- Cheongju-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 398 worldwide
- Run by
- Hummingbird Bioscience
See details and how to joinNCT05910827 - Phase 2Taking peopleOsimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
- Where
- Seoul
- Age
- 30 years to 75 years
- People
- 43
- Run by
- Samsung Medical Center
See details and how to joinNCT04591002 - Phase 2Taking peopleOsimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
- Where
- Seoul
- Age
- 30 years to 75 years
- People
- 59
- Run by
- Samsung Medical Center
See details and how to joinNCT05528458 - Phase 2Taking peopleSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
- Where
- Cheongju-si, Incheon, Jinju, Seoul
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06841055 · EU 2024-518279-80-00 - Phase 4Taking peopleAnesthesia and Non-small Cell Lung Cancer Recurrence
- Where
- Seoul
- Age
- 19 years and over
- People
- 5,384
- Run by
- Samsung Medical Center
See details and how to joinNCT06330038 - No phaseTaking peopleLow (-4) vs Physiologic (-8) Pressure Digital Continuous Suction After Lung Resection
- Where
- Seoul
- Age
- 19 years and over
- People
- 160
- Run by
- Seoul National University Hospital
See details and how to joinNCT07527702 - Phase 1Taking peoplePhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Where
- Cheongju-si, Goyang-si, Jinju, Seoul
- Age
- 18 years and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00 - No phaseTaking peoplePost Marketing Surveillance(PMS) Study of Lorviqua in Korea
- Where
- Seoul
- Age
- 18 years and over
- People
- 600
- Run by
- Pfizer
See details and how to joinNCT05599412 - Phase 1Taking peopleA Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
- Where
- Goyang-si, Seongnam, Seoul
- Age
- 19 years and over
- People
- 70
- Run by
- Aptamer Sciences, Inc.
See details and how to joinNCT06687941 - No phaseTaking peopleShape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea
- Where
- Ulsan
- Age
- 19 years and over
- People
- 100
- Run by
- Ulsan University Hospital
See details and how to joinNCT07057648 - No phaseTaking peopleEvaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
- Where
- Busan, Goyang, Incheon, Jinju, Ulsan
- Age
- 19 years and over
- People
- 414
- Run by
- Ulsan University Hospital
See details and how to joinNCT07405931 - Phase 2Enrolling by invitationEfficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
- Where
- Seoul
- Age
- 20 years and over
- People
- 27
- Run by
- Yonsei University
See details and how to joinNCT06250777